ients Could Benefit from FDA Approval
Selected Abstract
The International Myeloma Foundation Says Previously Untreated Patients Could Benefit from FDA Approval of VELCADE(R) for 'Front-Line' Use.
New Indication Provides Treatment-Free Interval As an Option NORTH HOLLYWOOD, Calif. -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today applauded the decision by the US ... June 23, 2008; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles No Results Found.
|
